Cornelius Stephen Harlacher

Title: Cornelius Stephen Harlacher: Innovator in Cancer Treatment

Introduction

Cornelius Stephen Harlacher is a notable inventor based in Reinach, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of treatments for cancer. His innovative work has led to the creation of a patent that addresses critical medical needs.

Latest Patents

Harlacher holds a patent for "Crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide as Raf inhibitors for the treatment of cancer." This invention relates to crystalline forms of the compound and processes for their preparation. Furthermore, it includes a pharmaceutical composition that comprises these crystalline forms along with at least one pharmaceutically acceptable excipient. The composition is intended for use as a medicament, specifically for the treatment of various cancers.

Career Highlights

Harlacher is associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to focus on innovative solutions in the pharmaceutical industry. His contributions have been instrumental in advancing cancer treatment options.

Collaborations

Harlacher has collaborated with notable colleagues, including Zaixing Li and Liladhar Murlidhar Waykole. These collaborations have further enhanced the research and development of effective cancer therapies.

Conclusion

Cornelius Stephen Harlacher's innovative work in the pharmaceutical field exemplifies the impact of dedicated inventors on healthcare. His patent for crystalline forms of a cancer treatment compound highlights the importance of innovation in addressing critical medical challenges.